Purcell Michael J. 4

What Happened Michael J. Purcell, a director of Hepion Pharmaceuticals, reported an open-market purchase of 1,250,000 shares on April 21, 2026. The shares were acquired at $0.04 each for a total reported outlay of $50,000 (transaction code P). This was a purchase (buy) rather than a sale.

Key Details

• Transaction date: 2026-04-21; Form 4 filed: 2026-04-27 (filed six days after the transaction; outside the typical two-business-day Form 4 window).
• Transaction type/code: Open-market purchase (Code P).
• Shares purchased: 1,250,000 at $0.04 per share; total value $50,000.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/plan info: No 10b5-1 plan or special footnotes disclosed in the filing excerpt.
• Insider status: Director (not identified as a 10% owner in the provided data).

Context Insider purchases can be informative to retail investors, but this purchase's modest dollar value relative to many insider trades means it should be viewed as one data point rather than a definitive signal. Also note the filing was submitted several days after the trade, which is later than the usual two-business-day reporting requirement.